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In accordance with this
interpretation, the anlage of the
enteropneust and chordate mouths
map to opposite sides of the brain
rudiment [2], with the anlage of the
enteropneust mouth corresponding
to the proposed location of the
obliterated mouth in chordates [3–5].
So, if one equates the
conventional ventral side of
enteropneusts with the dorsal side of
the chordates, then in both body
plans the brain plus (principal) nerve
cord, as well as the pygochord or
notochord, the direction of blood flow
and the hepatic structures coincide
(Fig. 1). In the future, expression
patterns of orthologous genes should
help to assess the hypothesis that
enteropneusts conceptually link the
articulate and chordate body plans,
provided that we compare the ventral
side of enteropneusts with the dorsal
side of chordates.
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Gazetteer
Biogen, Inc.
What is it famous for? Being one of
the first biotechnology companies, and
the oldest one still to be independent.
How did it start? It was founded in
1978 by an international group of
scientific luminaries, including
Phillip Sharp, Kenneth Murray and
Walter Gilbert. Sharp is currently
chairman of the scientific board.
Does it actually sell any products?
Not yet. Like most biotechnology
firms, Biogen started out by licensing
its most promising products to larger
firms in return for royalties on sales.
Interferon-a was licensed to
Schering-Plough, and recombinant
hepatitis B antigens, used for
vaccines, were licensed to SmithKline
Beecham and to Merck. But Biogen
should soon start to market a product
of its very own, interferon-b1A.
What is interferon-b1A good for?  In
December 1995, an advisory
committee recommended the US
Federal Drug Agency approve its use
as a treatment for relapsing forms of
multiple sclerosis (MS). In a Phase III
trial, treatment with the drug reduced
the progression of patients with MS by
40 % — by an unknown mechanism. 
What else is it working on? Most of
the products in preclinical or early
clinical development are immuno-
suppressants: for example, an
antibody to VLA-4 which should stop
lymphocyte traffic through blood
vessel walls, and an engineered
antibody-like molecule that seems to
inhibit T-cell proliferation.
Does the company make a profit?
Usually. In 1993, it made a profit of
$32.4 million, in 1994 a loss of
$4.9 million, and in 1995 a profit
again, to the tune of $5.6 million. The
main reason for the loss in 1994 was a
cost of $25 million for stopping work
on Hirulog, a leech-derived thrombin
inhibitor, after a Phase III trial
showed that it was no better than
heparin at preventing clot formation. 
Where do the profits go?  Some are
reinvested, some go to individuals,
and some are funnelled into the
academic community. For example,
royalties paid to Kenneth Murray for
work on hepatitis B have been
donated to Edinburgh University
and the Darwin Trust, providing
funds for a new library, a biological
sciences building, graduate students
and postdoctoral fellows.  
How does it compare with other
biotechnology companies? As a profit-
making company, however erratic,
Biogen probably rates as one of the
top five biotechnology companies. At
around 500 employees, it doesn’t
compare in size with Amgen or
Genentech, but there aren’t many
other larger biotech companies.
How much does it put into research?
In 1995, Biogen’s total revenues were
$151.7 million, of which $87.4 million
was spent on research and
development. R & D staff number
186; Biogen currently employs 88
PhDs and MDs in total. The
expectation of new revenues from
interferon-b1A sales has triggered a
hiring frenzy in all parts of the
company; jobs on offer can be found
on Biogen’s web site (http://www.
careermosaic.com/cm/biogen/).
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